Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 11Neoplasm Metastasis 3Neoplasms 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Pain 1Osteoporosis 1Lung Neoplasms 1Kidney Neoplasms 1Hypertension 1Gastrointestinal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 11pembrolizumab 8enfortumab vedotin 8Specimen Handling 8Cisplatin 8Magnetic Resonance Spectroscopy 6avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Biopsy 3cabozantinib 2Standard of Care 2Ramucirumab 2Platinum 2Ipilimumab 2Immunoglobulin G 2Doxorubicin 2Docetaxel 2Disulfides 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1relatlimab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Vitamin D × Genitourinary × Clear all
NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

University Health Network, Toronto

Phase 2 Completed
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡